Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Goodwill & Intangibles (2017 - 2025)

Historic Goodwill & Intangibles for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to $217.3 million.

  • Ultragenyx Pharmaceutical's Goodwill & Intangibles rose 382.19% to $217.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.3 million, marking a year-over-year increase of 382.19%. This contributed to the annual value of $222.7 million for FY2024, which is 208.04% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Goodwill & Intangibles is $217.3 million, which was up 382.19% from $219.1 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Goodwill & Intangibles registered a high of $222.7 million during Q4 2024, and its lowest value of $175.3 million during Q3 2021.
  • For the 5-year period, Ultragenyx Pharmaceutical's Goodwill & Intangibles averaged around $203.0 million, with its median value being $204.4 million (2022).
  • In the last 5 years, Ultragenyx Pharmaceutical's Goodwill & Intangibles surged by 1849.94% in 2022 and then crashed by 54.19% in 2023.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Goodwill & Intangibles stood at $175.7 million in 2021, then rose by 18.5% to $208.2 million in 2022, then increased by 4.8% to $218.2 million in 2023, then increased by 2.08% to $222.7 million in 2024, then dropped by 2.41% to $217.3 million in 2025.
  • Its last three reported values are $217.3 million in Q3 2025, $219.1 million for Q2 2025, and $220.9 million during Q1 2025.